Injection site with generalized rash caused by pegylated interferon alpha 2a injection.
Kawada
Kayoko
K
Maeda
Naoto
N
Kobayashi
Sawako
S
Sowa
Junko
J
Tsuruta
Daisuke
D
Kawada
Norifumi
N
D000284:Administration, Oral; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005076:Exanthema / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D005477:Fluprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009824:Ointments; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000998:Antiviral Agents; D006634:Histamine H1 Antagonists; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009824:Ointments; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D005477:Fluprednisolone; C100416:peginterferon alfa-2a; C015808:difluprednate